IN THE CLAIMS

Amendments to the Claims:

Please cancel claims 1-74, without prejudice or disclaimer and add claims 75-95.

Following amendments, claims 75-95 will be pending in the application.

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-74. (Cancelled)

75. (new) A method of reducing low density lipoprotein (LDL) while not significantly reducing high density lipoprotein (HDL) in a human subject, which method comprises administering over time a composition comprising a mixture of theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate, and theaflavin 3,3'-digallate in a quantity and for a time period sufficient to reduce the LDL while not significantly reducing the HDL over the time of administration.

76. (new) The method of claim 75, wherein the administration is continued for at least four weeks.

77. (new) The method of claim 76, wherein the administration is continued for at least twelve weeks.

78. (new) The method of any of claims 75-77, wherein the theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate, and theaflavin 3,3'-digallate mixture is administered to the subject at a daily dosage rate of about 0.001mg/kg to about 200mg/kg body weight of the subject.

79. (new) The method of claim 78, wherein the theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate, and theaflavin 3,3'-digallate mixture is administered at the daily dosage rate of about 0.1mg/kg to about 5mg/kg body weight of the subject.

80. (new) The method of claim 75, wherein the administration is by oral composition.

81. (new) The method of claim 80, wherein the oral composition is a tablet, capsule, or powder.

82. (new) The method of claim 80, wherein the oral composition contains the theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate, and theaflavin 3,3'-digallate mixture in purified form in combination with a pharmaceutically acceptable vehicle.

83. (new) The method of claim 82, wherein the theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate, and theaflavin 3,3'-digallate mixture is present at a level of about 5% to about 50% (w/w) of the composition administered.

84. (new)The method of claim 75, wherein the human subject suffers from hyperlipidemia

85. (new) A daily dosage composition suitable for oral administration to a human subject over time, which dosage composition comprises a mixture of theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate, and theaflavin 3,3'-digallate in an amount sufficient to reduce low density lipoprotein (LDL) while not significantly reducing high density lipoprotein (HDL), when the composition is delivered on a daily basis over time.

86. (new) The dosage form of claim 85, wherein the dosage form is a tablet, capsule, or powder.

87. (new) The dosage form of claim 85, wherein the theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate, and theaflavin 3,3'-digallate of the composition is in purified form and is combined with a pharmaceutically acceptable vehicle.

88. (new) The dosage form of claim 87, wherein the theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate, and theaflavin 3,3'-digallate of the composition is present at a level of about 5% to about 50% (w/w) of the dosage form.

89. (new) The dosage form of claim 85 as a water-based liquid.

90. (new) The dosage form of claim 85, wherein the mixture is combined with vegetable oil.

91. (new) The dosage form of claim 90, wherein the mixture combined with vegetable oil is encapsulated in a capsule.

92. (new) The dosage form of claim 90, wherein the vegetable oil is chosen from corn oil, peanut oil, safflower oil, sunflower oil, and soybean oil.

93. (new) The composition of claim 85, wherein the composition is to be administered for at least 4 weeks.

94. (new) The composition of claim 92, wherein the composition is to be administered for at least 12 weeks.

95. (new) The composition of claim 85, wherein the composition is for administration to a human subject that exhibits hyperlipidemia.